IQVIA vs Symphony Which Is Stronger?

IQVIA Holdings Inc. (IQV) and Symphony Technology Group (Symphony) are two leading companies in the healthcare technology and data analytics industry. IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the healthcare industry. Symphony is a private equity firm that invests in companies focused on healthcare technology and information services. Both companies have experienced significant growth and success in recent years, making them attractive options for investors looking to capitalize on the booming healthcare technology market.

IQVIA or Symphony?

When comparing IQVIA and Symphony, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between IQVIA and Symphony.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. IQVIA has a dividend yield of -%, while Symphony has a dividend yield of 0.62%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. IQVIA reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Symphony reports a 5-year dividend growth of 0.00% year and a payout ratio of -10.14%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with IQVIA P/E ratio at 28.12 and Symphony's P/E ratio at -16.42. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. IQVIA P/B ratio is 5.67 while Symphony's P/B ratio is 0.99.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, IQVIA has seen a 5-year revenue growth of 0.60%, while Symphony's is -0.20%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with IQVIA's ROE at 21.50% and Symphony's ROE at -5.91%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $216.95 for IQVIA and HK$0.81 for Symphony. Over the past year, IQVIA's prices ranged from $191.45 to $261.73, with a yearly change of 36.71%. Symphony's prices fluctuated between HK$0.78 and HK$0.93, with a yearly change of 19.23%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.